Table 2.

Phase 2/3 clinical trials with sGC drugs in rare diseases

ME	Phase	Indication	NCT number	Study name	Status	Reference
Riociguat	3	PAH	NCT00810693	PATENT	Completed/approved	Ghofrani et al. 2013a
Riociguat	3	CTEPH	NCT00855465	CHEST	Completed/approved	Ghofrani et al. 2013b
Riociguat	3	PAH	NCT00863681	PATENT-2	Completed/approved	Rubin et al. 2015
Riociguat	3	CTEPH	NCT00910429	CHEST-2	Completed/approved	Simonneau et al. 2016
Riociguat	3	pediatric PAH	NCT02562235	PATENT-CHILD	Ongoing
Riociguat	3	PAH	NCT02007629	RESPITE	Completed	Hoeper et al. 2017
Riociguat	2	IIP	NCT02138825	RISE-IIP	Terminated	Nathan et al. 2019
Riociguat	2	SSc	NCT02283762	RISE-SSc	Completed	Distler et al. 2017
Riociguat	2	SCD	NCT02633397	STERIO-SCD	Ongoing
Olinciguat	2	SCD	NCT03285178	STRONG-SCD	Ongoing
Olinciguat	2	Achalasia	NCT02931565		Completed